Benjamin J. Bovell-Ammon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Benjamin J. Bovell-Ammon has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Alexander Y. Walley
Department of Medicine, Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts
1 shared publication- Alexander Y. Walley
Grayken Center for Addiction and Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Boston Medical Center and Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA; Bureau of Substance Addiction Services, Massachusetts Department of Public Health, Boston, MA, USA
1 shared publication Devon Dunn
Massachusetts Department of Public Health, Boston, Massachusetts
1 shared publication- Devon Dunn
Massachusetts Department of Public Health, 250 Washington Street, 6th Floor, Boston, MA 02108, USA
1 shared publication Elizabeth A. Evans
Department of Health Promotion and Policy, University of Massachusetts Amherst School of Public Health & Health Sciences, Amherst
1 shared publication- Elizabeth Evans
Department of Health Promotion and Policy, School of Public Health and Health Sciences, University of Massachusetts Amherst, Amherst, USA
1 shared publication
Latest Publications
- 16 July 2024
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 262, 111392
Receipt of medications for opioid use disorder before and after incarceration in Massachusetts State prisons, 2014-2019
- 16 July 2024
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 262, 111392
Receipt of medications for opioid use disorder before and after incarceration in Massachusetts State prisons, 2014-2019
- Open Access
- 4 March 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (3) , e242732
Prison Buprenorphine Implementation and Postrelease Opioid Use Disorder Outcomes
Despite a high risk of opioid overdose in the first weeks after release from incarceration,1-6 most jails and prisons in the US do not routinely offer medications for opioid use disorder (MOUD) to patients during incarceration or upon release.7-11 The National Academy of Sciences, Engineering, and Medicine recommends that all forms of MOUD approved by the Food and Drug Administration (FDA) be available and accessible in all care venues, particularly carceral settings,12 and more jurisdictions have been adopting MOUD in recent years.13
- 4 March 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (3) , e242732
Open AccessPrison Buprenorphine Implementation and Postrelease Opioid Use Disorder Outcomes
Despite a high risk of opioid overdose in the first weeks after release from incarceration,1-6 most jails and prisons in the US do not routinely offer medications for opioid use disorder (MOUD) to patients during incarceration or upon release.7-11 The National Academy of Sciences, Engineering, and Medicine recommends that all forms of MOUD approved by the Food and Drug Administration (FDA) be available and accessible in all care venues, particularly carceral settings,12 and more jurisdictions have been adopting MOUD in recent years.13